China Resources Double-Crane Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Income for the year ending December 31, 2023: USD 213.39 M

China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Income is USD 213.39 M for the year ending December 31, 2023, a 4.73% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Income for the year ending December 31, 2022 was USD 203.76 M, a 13.88% change year over year.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Income for the year ending December 31, 2021 was USD 178.93 M, a -4.99% change year over year.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Income for the year ending December 31, 2020 was USD 188.32 M, a 3.88% change year over year.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Operating Income for the year ending December 31, 2019 was USD 181.29 M, a 4.84% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
Shanghai Stock Exchange: 600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd.

CEO Mr. Wenchao Lu
IPO Date May 22, 1997
Location China
Headquarters No. 1, Lize East 2nd Road
Employees 12,269
Sector Health Care
Industries
Description

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

Similar companies

600058.SS

Minmetals Development Co., Ltd.

USD 0.95

1.76%

600085.SS

Beijing Tongrentang Co., Ltd

USD 5.16

2.25%

600007.SS

China World Trade Center Co., Ltd.

USD 3.20

0.78%

600056.SS

China Meheco Group Co., Ltd.

USD 1.47

2.19%

600008.SS

Beijing Capital Eco-environment Protection Group Co.,ltd.

USD 0.42

1.31%

StockViz Staff

January 15, 2025

Any question? Send us an email